What is InterCure?
InterCure, operating under the brand Canndoc, stands as the leading cannabis enterprise outside of North America. Its wholly owned subsidiary, Canndoc, is recognized as Israel's largest licensed cannabis producer, distinguished by its pharmaceutical-grade, Good Manufacturing Practices (GMP) certified medical cannabis products. InterCure's operational strength is built upon a robust, market-leading distribution network, strategic international partnerships, and a high-margin, vertically integrated "seed-to-sale" model. This comprehensive approach not only solidifies its dominant position in the Israeli market but also serves as a foundation for aggressive global expansion initiatives.
How much funding has InterCure raised?
InterCure has raised a total of $11M across 1 funding round:
Share Placement
$11M
Share Placement (2020): $11M, investors not publicly disclosed
What's next for InterCure?
With its substantial capital infusion and established market leadership, InterCure is strategically positioned for accelerated growth. The company's focus on global expansion, coupled with its vertically integrated model, suggests a trajectory aimed at capturing new markets and increasing market share. Future developments are likely to involve further strategic investments, potential acquisitions, and the expansion of its product portfolio to meet diverse international demands. The company's ability to leverage its existing infrastructure and partnerships will be key to its continued success in the dynamic global cannabis industry.
See full InterCure company page
